MoonLake Immunotherapeutics Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – MLTX

Core Viewpoint - The Gross Law Firm is notifying shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX) about a class action lawsuit due to alleged misleading statements regarding the company's drug candidate SLK and its comparison to BIMZELX [1][3]. Group 1: Allegations - The complaint alleges that during the class period from March 10, 2024, to September 29, 2025, the defendants made materially false and/or misleading statements [3]. - Specific allegations include that SLK and BIMZELX share the same molecular targets, and SLK's unique Nanobody structure does not provide a clinical benefit over BIMZELX's traditional monoclonal structure [3]. - It is also claimed that SLK's supposed increased tissue penetration would not lead to improved clinical efficacy, indicating that the defendants lacked a reasonable basis for their positive statements about SLK's superiority [3]. Group 2: Class Action Details - Shareholders who purchased MLTX shares during the specified class period are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for December 15, 2025 [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. - Participation in the case incurs no cost or obligation for the shareholders [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies engage in responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [5].